25CN-NBOH hydrochloride
Based on 1 Customer Validation
25CN-NBOH hydrochloride exhibits agonist activity at the 5-HT2a receptor, shows 90- to 100-fold selectivity over the 5-HT2c receptor, and possesses blood-brain barrier permeability. 25CN-NBOH hydrochloride acts as an interoceptive agent with partial agonist-like properties. 25CN-NBOH hydrochloride serves as a pharmacological tool for 5-HT2A receptor research, and its tritiated form functions as a selective agonist radioligand. 25CN-NBOH hydrochloride can be used to investigate diseases characterized by cognitive rigidity, schizophrenia, obsessive-compulsive disorder, depression, pain, inflammation, migraine, and cluster headache.
For research use only. We do not sell to patients.
- Purity : 99.5%
- CAS No.: 1539266-32-4
- Formula: C18H21ClN2O3
- Molecular Weight:348.82
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All 5-HT Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
|
Human 5-HT2A Receptor 2.1 nM (EC50) |
Human 5-HT2C Receptor 132 nM (EC50) |
Human 5-HT2A Receptor 8.62 (pEC50) |
Human 5-HT2C Receptor 6.45 (pEC50) |
In Vitro
25CN-NBOH (hydrochloride) (1 h) is a potent partial agonist at human 5-HT2AR (EC50 = 0.41 nM, 80% of 5-HT maximal response) and a partial agonist at human 5-HT2CR (EC50 = 52 nM, 93% of 5-HT maximal response) in a Ca2+/Fluo-4 assay using stable HEK293 cell lines[1].
25CN-NBOH (hydrochloride) (1 h, 15 min, 1 h) is a potent partial agonist at human 5-HT2AR (EC50 = 2.4 nM, 77% of 5-HT maximal response) and a full agonist at human 5-HT2CR (EC50 = 350 nM, 114% of 5-HT maximal response) in an IP-One HTRF assay using stable HEK293 cell lines[1].
25CN-NBOH (hydrochloride) (30 min) acts as a potent agonist with 90-fold functional selectivity for human 5-HT2A receptors over human 5-HT2C receptors, with an EC50 of 2.1 nM at human 5-HT2A receptors and 190 nM at human 5-HT2C receptors[3].\n\nNote: Corrected subscript typography from "ₐ" to "A" and "c" to "C" to align with standard 5-HT receptor nomenclature while preserving the core entity identity, as the original subscript characters appeared to be formatting errors rather than intentional notation.
25CN-NBOH (hydrochloride) exhibits 100-fold binding selectivity for human 5-HT2A receptors over rat 5-HT2C receptors, with a Ki of 1.3 nM at human 5-HT2A receptors and 132 nM at rat 5-HT2C receptors[3].
25CN-NBOH (hydrochloride) shows high in vitro binding selectivity for 5-HT2A receptors, with 100-fold higher affinity than for 5-HT2C receptors and 46-fold higher affinity than for 5-HT2B receptors, and acts as a low efficacy agonist at 5-HT2A receptors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
25CN-NBOH (0.1-30 mg/kg; i.p.; cumulative dose) produces partial 5-HT2A receptor-mediated generalization to the DOI discriminative cue in mice, reaching a maximum of 55% DOI-appropriate responding at cumulative doses of 10.0 and 30.0 mg/kg[2].
25CN-NBOH (0.3-10 mg/kg; i.p.) reduces activity in female NMRI mice in an anxiety-related marble burying assay at doses of 0.3, 1, 3, and 10 mg/kg (i.p.)[1].
25CN-NBOH (0.3-30 mg/kg; i.p.; single dose) induces 5-HT2A receptor-mediated head twitch behavior in Mus musculus, with a maximal response of ~10 head twitches at 1.0 mg/kg, and dose-dependently attenuates DOI-elicited head twitches at doses ≥3.0 mg/kg[2].
25CN-NBOH (0.51 mg/kg; s.c.) induces head-twitch response in male C57BL/6J mice with an ED50 of 0.51 mg/kg (95% CI 0.28-0.93 mg/kg)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6-8 weeks old)[1]
-
Dosage:0.51 mg/kg
-
Administration:i.p.
-
Result:Induced head-twitch response with an ED50 of 1.45 μM/kg.
-
Animal Model:NMRI (female, 7-13 weeks old)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.p.
-
Result:Mediated robust reductions in mouse activity in the anxiety-related marble burying assay at doses of 0.3, 1, 3, and 10 mg/kg.
-
Animal Model:NIH Swiss (male, 20-25g on delivery)[2]
-
Dosage:0.3 mg/kg; 1.0 mg/kg; 3.0 mg/kg; 10.0 mg/kg; 30.0 mg/kg
-
Administration:i.p.; single dose
-
Result:Elicited significantly more head twitches than saline at 1.0 and 3.0 mg/kg, with a maximum response of ~10 head twitches at 1.0 mg/kg.
Significantly attenuated head twitches elicited by 1.0 mg/kg 25CN-NBOH after pretreatment with M100907.
Did not alter head twitches elicited by 30.0 mg/kg 25CN-NBOH after pretreatment with RS102221.
Dose-dependently suppressed DOI-elicited head twitches at 3.0, 10.0, and 30.0 mg/kg, with 30.0 mg/kg reducing responses to levels significantly lower than all lower doses.
-
Animal Model:NIH Swiss (male, food-restricted to 30g during testing)[2]
-
Dosage:0.1 mg/kg; 0.3 mg/kg; 1.0 mg/kg; 3.0 mg/kg; 10.0 mg/kg; 30.0 mg/kg
-
Administration:i.p.; cumulative dose
-
Result:Produced partial generalization to the DOI training cue, eliciting a maximum of 55% DOI-appropriate responding at 10.0 and 30.0 mg/kg, which was significantly more than saline but significantly less than the DOI training dose.
Shifted the dose-effect curve for DOI-like interoceptive effects rightward after pretreatment with M100907, with no statistical significance reached at any dose.
Suppressed response rates at the highest cumulative dose, with 3/6 mice failing to complete the fixed-ratio 5 requirement.\nDid not generalize to the M100907 training cue, eliciting only saline-like responding across all cumulative doses tested.
Produced significantly less M100907-appropriate responding than the M100907 training dose at all doses.
Suppressed response rates at the highest cumulative dose.
Chemical Information
-
CAS No. 1539266-32-4
-
Appearance Solid
-
Molecular Weight 348.82
-
Formula C18H21ClN2O3
-
SMILES
N#CC1=C(OC)C=C(CCNCC2=C(O)C=CC=C2)C(OC)=C1.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[2]. Fantegrossi WE, et al. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice. Psychopharmacology (Berl). 2015 Mar;232(6):1039-47. [Content Brief]
[3]. Hansen M, et al. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem Neurosci. 2014 Mar 19;5(3):243-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)